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We read with interest the publication of Schmiedl et al. [1]
describing the characteristics of patients treated with
tiotropium HandiHaler® or Respimat® in the Tiotropium
Safety and Performance in Respimat (TIOSPIR®) study com-
pared with their ‘real-world’ database [2]. The authors noted
that patients starting either treatment had similar character-
istics but suggest that we may have included a selected popu-
lation with chronic obstructive pulmonary disease (COPD),
who might react differently to treatment (and be at lower risk
of cardiac adverse effects) than a ‘real-world’ population.
The baseline characteristics of the patients with COPD
enrolled in placebo-controlled tiotropium studies using
HandiHaler® or Respimat® were recently compared with those
from a range of epidemiological studies. Patients included in
tiotropium studies were found to be widely representative of
the overall COPD population [3]. While ‘real-world’ observa-
tional studies may be useful in generating relevant clinical
questions, randomized controlled trials, such as TIOSPIR®, use
robust methodologies designed and powered to answer these.
As Schmiedl et al. [1] note, one of the main reasons for their
‘real-world’ patients notmeeting the inclusion/exclusion criteria
of TIOSPIR® was a diagnosis of asthma. Indeed, a concomitant
diagnosis of asthma was an exclusion criterion in most studies
of tiotropium in COPD. On the other hand, tiotropium was in-
vestigated in a large clinical programme of patients with asthma
(including severe asthma, excluding COPD); a higher risk of
adverse cardiac effects in these patients was not identiﬁed [4].
Another criterion for exclusion from TIOSPIR® was milder
COPD [forced expiratory volume in 1 s (FEV1)>70% predicted].
While Schmiedl et al. [1] were right to highlight differences in their
‘real-world’ population from those meeting more stringent
criteria in clinical trials, there is no reason to believe that pa-
tients with milder disease would be at any additional speciﬁc
risk for adverse cardiac effects with tiotropium treatment be-
yond the assessments performed in TIOSPIR®. On the contrary,
as TIOSPIR® was a safety study, and therefore focused on
patients with more severe respiratory disease, it would be
expected that any safety signal would be more evident than in
an overall ‘real-world’ population, which was not the case.
Owing to the speciﬁc exclusion criteria of tiotropium trials,
some differences in characteristics compared with patients in
clinical practice do remain. For example, TIOSPIR® [2] [and also
the 4-year Understanding Potential Long-term Impacts on
Function with Tiotropium (UPLIFT®) trial of tiotropium
HandiHaler®] [5] excluded patients with moderate-to-severe
renal impairment. However, a pooled analysis of 22 blinded,
placebo-controlled studies of tiotropium HandiHaler® and
Respimat® in which baseline serum creatinine was collected
did not indicate an increased risk for all-cause or cardiac mortal-
ity, or serious adverse events, in patients with COPD and
existing mild-to-moderate renal impairment [3, 6–8].
Patients with recent severe cardiac events [myocardial infarc-
tion within ≤6 months, unstable/life-threatening arrhythmia re-
quiring intervention or change in treatment, or hospitalization
with severe (New York Heart Association class III/IV) cardiac fail-
ure within ≤1 year] were also excluded from tiotropium trials
[9]. To investigate the safety of tiotropium in patients with a re-
cent history of cardiac events, patients in UPLIFT® and TIOSPIR®
were followed up for mortality and cardiac adverse events
occurring after an initial on-treatment cardiac event, while con-
tinuing on therapy. Neither the results for tiotropium
HandiHaler® vs. placebo (UPLIFT®) [10], nor for tiotropium
Respimat® vs. HandiHaler® (TIOSPIR®) [11], indicated a speciﬁc risk
for subsequent mortality or cardiac events in this high-risk group.
Another possible confounder could be the selection of pa-
tients with high tolerability for anticholinergic agents (i.e.
pretreated with this class of drug). While this could explain the
variation in results between TIOSPIR® and some epidemiological
studies, the analysis of a large group of patients from TIOSPIR®
who were anticholinergic-naïve at baseline did not indicate any
differential effects vs. the total study population, or between
the tiotropium HandiHaler® and Respimat® groups [12].
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To conclude, while it is true that certain groups of patients
may be under-represented in individual studies of tiotropium,
the very large clinical trial database [9] (including long-term
studies of up to 4 years’ duration) allows for comprehensive sub-
group analyses of patients potentially at risk and, in our opin-
ion, supports the safety of tiotropium in these patients.
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